EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dynamic Changes in Circulating Tumor DNA During Immunotherapy for Head and Neck Cancer: SHIZUKU-HN Study

Rika Noji, Kohki Tohyama, Shin Nakamura, Takahiro Naito, Yu Oikawa, Takeshi Kuroshima iD, Hirofumi Tomioka, Yasuyuki Michi iD, Sadakatsu Ikeda, Takahiro Asakage, Masahiko Miura iD, Yasuo Hamamoto iD und 2 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms26010235 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Rika Noji und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgical Oncology, Division of Health Science, Graduate School of Medical and Dental Sciences, Institute of Scie…. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck, Immunotherapy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI, TMDU Research Grant for the Utilization of Big Data.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) are effective in treating recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), but only 20% of patients achieve durable responses. This study evaluated circulating tumor DNA (ctDNA) as a real-time biomarker for monitoring treatment response in HNSCC. The SHIZUKU-HN study prospectively collected and analyzed serial plasma samples (n = 27) from HNSCC patients undergoing ICIs, using Guardant360 to assess ctDNA variant allele frequency (VAF) and genetic mutations. Tumor volumes were quantified using 3D reconstruction of CT scans, and data from Japan’s C-CAT database (n = 2255) provided insights into ctDNA testing in HNSCC. C-CAT data showed that ctDNA testing was underutilized, performed in only 7% of head and neck cancer cases. In SHIZUKU-HN, mean VAF significantly correlated with tumor volume (Spearman’s ρ = 0.70, p = 0.001), often preceding radiographic progression. BRAF and APC mutations disappeared in partial responders, while GNAS mutations varied. EGFR and PIK3CA amplifications, detectable via ctDNA but missed in tissue biopsies, indicated emerging resistance mechanisms. The SHIZUKU-HN study demonstrates the potential of ctDNA as a dynamic biomarker in HNSCC, offering early insights into treatment efficacy and informing personalized ICI therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNAHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckImmunotherapyImmune Checkpoint InhibitorsHumansMaleFemaleBiomarkers, TumorMiddle AgedAgedMutationClass I Phosphatidylinositol 3-KinasesAdultProspective StudiesAged, 80 and over

Stichwörter der Autor:innen

Center for Cancer Genomics and Advanced Therapeutics (C-CAT)circulating tumor DNA (ctDNA)dynamic monitoringhead and neck squamous cell carcinoma (HNSCC)immune checkpoint inhibitor (ICI)liquid biopsyvariant allele frequency (VAF)

Substanzen

Circulating Tumor DNABiomarkers, TumorImmune Checkpoint InhibitorsClass I Phosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • Department of Oral and Maxillofacial Surgical Oncology, Division of Health Science, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-Ku, Tokyo 113-8510, Japan.
  • Department of Medical Oncology, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-Ku, Tokyo 113-8510, Japan.
  • Department of Dental Radiology and Radiation Oncology, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-Ku, Tokyo 113-8510, Japan.
  • Department of Precision Cancer Medicine, Center for Innovative Cancer Treatment, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-Ku, Tokyo 113-8510, Japan.
  • Department of Head and Neck Surgery, Institute of Science Tokyo 1-5-45 Yushima, Bunkyo-Ku, Tokyo 113-8510, Japan.

ORCID-Profile: Takeshi Kuroshima, Yasuyuki Michi, Masahiko Miura, Yasuo Hamamoto, Yoshihito Kano

Förderung

  • JSPS KAKENHI
  • TMDU Research Grant for the Utilization of Big Data

Zitieren

APA

Noji, R., Tohyama, K., Nakamura, S., Naito, T., Oikawa, Y., Kuroshima, T., Tomioka, H., Michi, Y., Ikeda, S., Asakage, T., Miura, M., Hamamoto, Y., Harada, H., & Kano, Y. (2024). Dynamic Changes in Circulating Tumor DNA During Immunotherapy for Head and Neck Cancer: SHIZUKU-HN Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26010235

Vancouver

Noji R, Tohyama K, Nakamura S, Naito T, Oikawa Y, Kuroshima T, et al. Dynamic Changes in Circulating Tumor DNA During Immunotherapy for Head and Neck Cancer: SHIZUKU-HN Study. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms26010235

BibTeX
@article{Noji2024,
  author = {Noji, Rika and Tohyama, Kohki and Nakamura, Shin and Naito, Takahiro and Oikawa, Yu and Kuroshima, Takeshi and Tomioka, Hirofumi and Michi, Yasuyuki and Ikeda, Sadakatsu and Asakage, Takahiro and Miura, Masahiko and Hamamoto, Yasuo and Harada, Hiroyuki and Kano, Yoshihito},
  title = {Dynamic Changes in Circulating Tumor DNA During Immunotherapy for Head and Neck Cancer: SHIZUKU-HN Study},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms26010235}
}
Kostenlos starten →